New drug combo tested to shrink tumors before cancer surgery
NCT ID NCT01927744
Summary
This study tested whether adding the drug erlotinib to standard chemotherapy helps control head and neck cancer before surgery. Fifty-five patients with operable oral cavity cancer were randomly assigned to receive either the standard chemo combination plus erlotinib or plus a placebo pill. Researchers measured how much tumor was left after treatment to see if the erlotinib combination was more effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.